NCT00360906View on ClinicalTrials.gov

Omega-3 Fatty Acid Treatment in Multiple Sclerosis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 31, 2004

Study Completion Date

July 31, 2008

Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
DRUG

Triomar™ (omega-3 fatty acids)

Trial Locations (1)

N-5021

Department of Neurology, Haukeland University Hospital, Bergen

Sponsors
All Listed Sponsors
collaborator

The Multiple Sclerosis National Competence Centre

UNKNOWN

collaborator

The Norwegian Multiple sclerosis Society

UNKNOWN

collaborator

Pronova BioPharma

INDUSTRY

collaborator

Serono Nordic

UNKNOWN

collaborator

Amersham Health

INDUSTRY

lead

Haukeland University Hospital

OTHER